Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CAI:NIPH's Return-on-Tangible-Asset is ranked better than 71.1% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.89
vs CAI:NIPH: 8.09
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Return-on-Tangible-Asset Related Terms
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Return-on-Tangible-Asset Chart
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Annual Data
Trend
Jun24
Jun25
Return-on-Tangible-Asset
0.00
5.42
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Quarterly Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Return-on-Tangible-Asset vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 9.38% mean?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a Return-on-Tangible-Asset of 9.38% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors. This is 73% above median its historical median of 5.42. Over the past decade, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Return-on-Tangible-Asset has ranged from 5.42 to 8.09. According to the industry distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #291 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 28.9%.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Return-on-Tangible-Asset too high?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Return-on-Tangible-Asset of 9.38% is 73% above median its 10-year median of 5.42. Over the past 10 years, this metric has ranged from a low of 5.42 to a high of 8.09. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.89. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's value of 9.38% is 224.6% above this industry median. Based on the distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #291 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #291 out of 1007 companies for Return-on-Tangible-Asset. This puts El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.89. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's value of 9.38% is 224.6% above this benchmark. Historically, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's own Return-on-Tangible-Asset has ranged from 5.42 to 8.09 over the past decade. While the company's 10-year median is 5.42 vs. the industry median of 2.89, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.89, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Return-on-Tangible-Asset of 9.38% is 224.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Return-on-Tangible-Asset is 9.38%, which is 73% above median its own 10-year median of 5.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile stock overvalued right now?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a current Return-on-Tangible-Asset of 9.38%. The current Return-on-Tangible-Asset is 9.38%, which is 73% above median its 10-year median of 5.42 and 224.6% above the Drug Manufacturers industry median of 2.89. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH), the current Return-on-Tangible-Asset is 9.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile manufactures and markets pharmaceuticals, medicinal materials, chemical products and surgical threads and medical solutions.
28GF Score
Get the complete analysis for CAI:NIPH
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:NIPH has been successfully added to your 
